BioArctic AB
BRCTF
Rank in Stocks
#4805
BioArctic AB (publ) develops biological drugs for patients with central nervous... BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Share Price
$30.33
Last synced: 2026-11-06
Market Cap
$2.84B
Change (1 day)
0.00%
Change (1 year)
9.02%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade BioArctic AB (BRCTF)
Category
Healthcare
EPS for BioArctic AB (BRCTF)
EPS as of June 2026 TTM: $0.12
According to BioArctic AB's latest financial reports, its current EPS (TTM) is $0.12. At the end of 2025 the company had an EPS of $1.25, an increase over its 2024 EPS of $-0.18.
EPS history for BioArctic AB from 2015 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.12 | -90.31% |
| 2025 | $1.25 | -788.64% |
| 2024 | $-0.18 | -170.63% |
| 2023 | $0.26 | -2,153.60% |
| 2022 | $-0.01 | -91.68% |
| 2021 | $-0.15 | 59.22% |
| 2020 | $-0.09 | -188.14% |
| 2019 | $0.11 | -77.90% |
| 2018 | $0.48 | 1,701.86% |
| 2017 | $0.03 | -62.38% |
| 2016 | $0.07 | 921.43% |
| 2015 | $0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 12,831.46% |
US
|
|
| $-7.07 | -5,938.15% |
US
|
|
| $-5.29 | -4,468.29% |
AU
|
|
| $12.88 | 10,535.92% |
BE
|
|
| $21.56 | 17,703.47% |
NL
|
Questions about BioArctic AB's earnings per share (EPS)
What is BioArctic AB's earnings per share (EPS)?
BioArctic AB's earnings per share (EPS) over the last twelve months is $0.12, as of Jun 2026.
What was BioArctic AB's earnings per share (EPS) in 2025?
In 2025, BioArctic AB's earnings per share (EPS) was $1.25, compared with $-0.18 in 2024.
How has BioArctic AB's earnings per share (EPS) changed since 2020?
From 2020 to 2025, BioArctic AB's earnings per share (EPS) was highest in 2025 ($1.25) and lowest in 2024 ($-0.18).
How does BioArctic AB's earnings per share (EPS) compare with similar companies?
BioArctic AB's earnings per share (EPS) ($0.12) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.